Riverview Trust Co Has $31,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Riverview Trust Co increased its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 3,953.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,216 shares of the biopharmaceutical company’s stock after acquiring an additional 1,186 shares during the period. Riverview Trust Co’s holdings in Royalty Pharma were worth $31,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of RPRX. Swedbank AB lifted its position in shares of Royalty Pharma by 10.3% during the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after buying an additional 1,136,800 shares in the last quarter. State Street Corp raised its position in shares of Royalty Pharma by 0.3% in the third quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock valued at $269,215,000 after purchasing an additional 29,451 shares during the period. Geode Capital Management LLC grew its stake in Royalty Pharma by 6.1% in the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after buying an additional 417,490 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of Royalty Pharma by 44.7% in the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after purchasing an additional 936,900 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Royalty Pharma by 58.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after buying an additional 1,103,341 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $33.64 on Friday. The firm has a market cap of $19.39 billion, a price-to-earnings ratio of 23.20, a PEG ratio of 2.31 and a beta of 0.49. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a 50-day simple moving average of $30.06 and a two-hundred day simple moving average of $28.18. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be paid a $0.22 dividend. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.62%. Royalty Pharma’s dividend payout ratio (DPR) is presently 60.69%.

Analyst Ratings Changes

Several equities analysts recently commented on the company. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Royalty Pharma currently has a consensus rating of “Buy” and an average price target of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.